AbbVie ABBV stock has gained 24.0% compared with an increase of 34.3% for the industry in the past year, as seen in the chart below. Zacks Investment Research Image Source: Zacks Investment Research AbbVie lost patent protection for its blockbuster immunology drug Humira in the United States in January 2023. Before it lost patent exclusivity, Humira accounted for a significant percentage of AbbVie’s sales, around 37% in 2022. Amgen AMGN was the first company to launch its Humira biosimilar. Thereafter, several other biosimilar versions of Humira were launched in the United States. In the EU, Humira biosimilars were launched in October 2018 and have rapidly eroded international sales from the branded drug since then. However, AbbVie has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq. Let’s delve deeper. Successful New Drugs - Skyrizi and Rinvoq AbbVie’s newer products, Skyrizi and Rinvoq, are performing extremely well, bolstered by approvals in new indications, which are likely to support top-line growth in the next few years. AbbVie expects the combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $27 billion by 2027. These drugs have the potential to replace Humira. Meanwhile, new migraine drugs, Ubrelvy and Qulipta/Aquipta, represent a combined $3 billion-plus peak sales opportunity. Boosted by its new product launches, AbbVie expects to return to robust revenue growth in 2025 with a high single-digit CAGR through the end of the decade. Attractive Pipeline AbbVie has several early/mid-stage pipeline candidates that have blockbuster potential. The company expects several regulatory submissions and key data readouts in the next twelve months. In blood cancers and solid tumors, AbbVie has an exciting and diverse pipeline of promising new therapies like ABBV-383, a BCMA CD3 bispecific, in late-stage development for relapsed/refractory multiple myeloma and Teliso-V, a promising c-Met ADC in late-stage development for nonsquamous non-small cell lung cancer. AbbVie and partner Genmab’s GMAB Epkinly/Tepkinly (formerly epcoritamab) was approved for relapsed or refractory (r/r) third-line diffuse large B-cell lymphoma in the United States and EU in 2023 and for third-line r/r follicular lymphoma in the United States in June 2024. Accretive Acquisitions AbbVie has been on an acquisition spree lately, which is strengthening its pipeline. Particularly, it is signing several M&A deals in the immunology space, its core area. It is acquiring smaller biotechs which are making novel drugs for treating inflammatory bowel disease (IBD), which includes two conditions — Crohn's disease (“CD") and ulcerative colitis (“UC”). In recent years, there has been a surge in the prevalence of IBD conditions, CD and UC, which has attracted big drugmakers’ attention to this space. In May, AbbVie closed its previously announced acquisition of Landos Biopharma, which added Landos’ lead pipeline candidate, NX-13, a first-in-class, oral NLRX1 agonist in phase II development for the treatment of UC. In June, AbbVie in-licensed exclusive global rights to develop and commercialize FG-M701, a next-generation TL1A antibody for the treatment of IBD indications from the Chinese biotech FutureGen Biopharmaceutical. In the same month, it also acquired Celsius Therapeutics, a private biotech making novel therapies for IBD diseases. Among some larger deals, AbbVie acquired ImmunoGen last year, which added the latter’s antibody-drug conjugate (ADC) for ovarian cancer, Elahere, to AbbVie’s oncology portfolio. In December last year, it announced the acquisition of neuroscience drugmaker, Cerevel Therapeutics CERE. The deal is expected to close soon. Attractive Valuation & Rising Estimates (for 2025) From a valuation standpoint, AbbVie appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 14.37 forward earnings, lower than 20.38 for the industry. ABBV Stock Valuation Zacks Investment Research Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings for 2024 has declined from $11.25 to $11.19 per share over the past 60 days. However, for 2025, earnings estimates have risen from $12.07 to $12.10 per share over the past 60 days. ABBV Estimate Movement Zacks Investment Research Image Source: Zacks Investment Research The stock’s return on equity on a trailing twelve-month basis is 179.47%, which is higher than 26.02% for the large drugmaker industry, as seen in the chart below. ABBV Return on Equity Zacks Investment Research Image Source: Zacks Investment Research Conclusion AbbVie faces its share of headwinds like Humira biosimilar erosion, increasing competitive pressure on cancer drug Imbruvica and decreased demand for fillers in international markets. Its Parkinson’s candidate, ABBV-951, has hit a roadblock, having faced the FDA’s rejection twice. However, AbbVie’s key drugs Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elahere, Epkinly and Qulipta, are expected to continue to drive top-line growth. Importantly, the erosion in Humira sales in the United States has been better than management’s expectations. New chief executive officer, Robert Michael, has been part of AbbVie since its formation and played a key role in establishing its financial planning organization, diversifying its business strategy, navigating the company through Humira’s loss of exclusivity and supporting important M&A activity. The stock has an attractive dividend yield of around 3.7%. Investors who own AbbVie’s stock may stay invested as the company has faced its biggest challenge — Humira’s patent cliff — quite well and looks set to return to robust growth next year. Buying AbbVie’s stock at its present reasonable valuation can prove prudent for long-term investors. AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN):Free Stock Analysis Report AbbVie Inc. (ABBV):Free Stock Analysis Report Cerevel Therapeutics Holdings, Inc. (CERE):Free Stock Analysis Report Genmab A/S Sponsored ADR (GMAB):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...